Conjugate vaccines are vaccines for infectious diseases. There are special polysaccharide coatings on some bacteria and viruses that help them to escape the immune system. An immature immune system can recognize these bacteria with the help of the conjugate vaccines, as these vaccines link the special polysaccharide coatings to an organism by producing immunity and response. The examples of conjugate vaccines are meningococcal vaccine to prevent meningitis, haemophilus influenzae type B (Hib) vaccine, and pneumococcal vaccine.
Increased revenue from the sale of meningococcal vaccines and pneumococcal vaccines are driving the global conjugate vaccine market due to increasing advancements in the research and development. Increasing prevalence of infectious diseases and rising awareness toward prevention of these disease is anticipated to boost the global conjugate vaccine market during the forecast period. However, long time interval between the introduction of new conjugate vaccines in low-income countries and high-income countries is likely to restrain the global conjugate vaccine market. According to the U.S. National Library of Medicine, National Institutes of Health, high mortality and morbidity are caused due to vaccine-preventable diseases. In 2010, 87% of the population of high-income countries had pneumococcal conjugate vaccines in their immunization schedules, whereas only 2% had pneumococcal conjugate vaccines in their immunization schedules among the total population of low-income countries.
The global conjugate vaccine market can be classified on the basis of product type, disease indication, pathogen type, patient type, and region. In terms of product type, the global conjugate vaccine market can be segmented into multivalent conjugate vaccines and monovalent conjugate vaccines. The monovalent conjugate vaccines segment held the major share of the market in 2016 due to the high awareness and high quality vaccines provided by key players. However, the multivalent conjugate vaccines segment is anticipated to expand in the near future due to the improvements in technology and government initiatives.
In terms of disease indication, the global conjugate vaccine market can be segmented into meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and others. The diphtheria tetanus pertussis segment of the global conjugate vaccine market expanded in 2016 due to its high prevalence and highly contagious nature of the respiratory tract infection. The pneumococcal segment of the global conjugate vaccine market is anticipated to expand during the forecast period, as it is the most attractive segment in the market, in terms of technology. In terms of pathogen type, the global conjugate vaccine market can be segmented into combination (viral and bacterial) conjugate vaccine, viral conjugate vaccine, and bacterial conjugate vaccine. In terms of patient type, the market can be segmented into adults conjugate vaccine and pediatrics conjugate vaccine. The pediatrics conjugate vaccine segment held a major share of the global market in 2016 due to the high prevalence of infectious diseases among children.
Geographically, the global conjugate vaccine market can be segmented into Asia Pacific, Europe, North America, Latin America, and Middle East & Africa. In terms of technology, North America is projected to be the most attractive market for conjugate vaccine during the forecast period, due to rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. The market in Asia Pacific is anticipated to expand during the forecast period due to increasing immunization initiatives by organizations such as GAVI and World Health Organization in emerging economies such as India and China. Increasing focus of major players on the market in India and governmental initiatives for infectious diseases are likely to fuel the demand for the conjugate vaccines in the region.
Key players operating in the global conjugate vaccine market include Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Pfizer, Inc., Novartis AG, Neuron Biotech, Merck & Co., Inc., GlaxoSmithKline plc, CSL Behring, Biological E, and Bharat Biotech.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.